Clinical trials: Non-Specific Effects of Vaccines
Healthy
Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine
The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune…
- Trial name
- VSG-2011-101 (NCT01578070)
- Testing
- 0.2μg Act-HIB®, ViscoGel® and 0.2μg Act-HIB®, ViscoGel® and 2μg Act-HIB®
- Where
- Sweden
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Viscogel AB